Back to discover
Disease

Sjogren's Syndrome

Late-stage therapeutic developmentEmerging research
MeSHSjogren's Syndrome
3
Publications
18
Clinical trials
2024
Latest publication
Current focus
Therapeutic developmentInflammation & immunityDisease mechanisms & pathology
Latest activity
beta

Recent clinical, regulatory, research and industry developments relating to this disease.

What's happening now

An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.

Executive briefingUpdating summary…Momentum: Low
Key developments
  • 2 clinical trials expected to report results, the earliest in Q3 2026.
Upcoming Milestones
Clinical Milestones7View
Results posted 1
Results expected 2
Recently completed 2
Other updates 2
Activity timeline7

Clinical trials

15 sponsors · 1 new · 0 completed in the last 12 months (net +0)

The current development programme across all trial phases.

Clinical programme
18
All trials
6
Active
8
Late-stage
6
Completed
Late-stage studies

Effectiveness of Belimumab After Rituximab in Resistant Primary Juvenile Sjogren's Syndrome

Phase 4 · Recruiting · Peking Union Medical College Hospital

A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Sjögren's Syndrome With Moderate-to-severe Systemic Disease Activity

Phase 3 · Active, not recruiting · Amgen

A Phase Ⅲ, Multi-center, Randomized, Placebo-controlled, Study to Evaluate the Efficacy and Safety of Subcutaneous Telitacicept in Subjects With Active Primary Sjogren's Syndrome

Phase 3 · Completed · RemeGen Co., Ltd.

Effects of CEQUA™ on Objective and Subjective Dry Eye Findings Associated With Sjogren's Syndrome

Phase 4 · Completed · Center for Ophthalmic and Vision Research, LLC

A Single-arm Investigator Initiated Study to Evaluate the Efficacy of OC-01 (Varenicline Solution) Nasal Spray on Signs and Symptoms of Dry Eye Disease in Subjects With Sjogren's Syndrome

Phase 4 · Completed · University of Pennsylvania

BAFF/IL-17 Bispecific Antibody Treatment in Subjects With Primary Sjogren's Syndrome

Phase 2/3 · Withdrawn · Matthew C. Baker
Recently completed

A Phase Ⅲ, Multi-center, Randomized, Placebo-controlled, Study to Evaluate the Efficacy and Safety of Subcutaneous Telitacicept in Subjects With Active Primary Sjogren's Syndrome

Phase 3 · Completed · RemeGen Co., Ltd.

Effects of CEQUA™ on Objective and Subjective Dry Eye Findings Associated With Sjogren's Syndrome

Phase 4 · Completed · Center for Ophthalmic and Vision Research, LLC

A Single-arm Investigator Initiated Study to Evaluate the Efficacy of OC-01 (Varenicline Solution) Nasal Spray on Signs and Symptoms of Dry Eye Disease in Subjects With Sjogren's Syndrome

Phase 4 · Completed · University of Pennsylvania

Randomised Double-blind Placebo-controlled Clinical Trial of Fish Oil (Omega 3 ) in Sjögren's Syndrome Patients

Phase 2/3 · Completed · Hawler Medical University

A Randomized Clinical Trial Evaluating Allogeneic Adipose-derived MesenchymAl Stem Cells as a Treatment of Dry Eye Disease in Patients With Sjögren's Syndrome

Phase 2 · Completed · Rigshospitalet, Denmark

Assessment of Inflammatory Biomarkers Expressed in a Sjogren's Population: Effect of a Topical Steroid Intervention

Phase 4 · Completed · Alcon Research

Research activity

3 papers

Key research shaping understanding of this disease, combining the latest publications with the most influential evidence.

Publications over time
20232024
Major themes8
  • Sjogren's Syndrome3
  • Autoimmune Diseases1
  • Fibrosis1
  • Lupus Erythematosus, Systemic1
  • Lymphoma, Large B-Cell, Diffuse1
  • Receptors, Chimeric Antigen1
  • Respiratory Distress Syndrome1
  • Salivary Glands1
Leading journals2
  • Frontiers in immunology2
  • Immunology letters1
Leading researchers8
  • Cao W1
  • Chen S1
  • Feng Y1
  • Jiang X1
  • Kroese FGM1
  • Li L1
  • Lin X1
  • Ma D1
Affiliations (unnormalised)6
  • Department of Neurology and Institute of Neurology1
  • Leiden University Medical Center1
  • Peking University Third Hospital1
  • Ruijin Hospital1
  • School of Chinese Medicine1
  • Shanghai Institute of Hematology1

Reference

Authoritative identity, definition & identifiers.

Defined in MeSH

Chronic inflammatory and autoimmune disease in which the salivary and lacrimal glands undergo progressive destruction by lymphocytes and plasma cells resulting in decreased production of saliva and tears. The primary form, often called sicca syndrome, involves both KERATOCONJUNCTIVITIS SICCA and XEROSTOMIA. The secondary form includes, in addition, the presence of a connective tissue disease, usually rheumatoid arthritis.

Identifiers
MeSHSjogren's Syndrome
References & data sources
  • Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
  • Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
  • Research activity — Europe PMC (EMBL-EBI) + OpenAlex-derived paper links
  • Related entities are derived from literature co-mention (studied together) — associative, not causal.